Key Takeaways KYTX stock jumped 41% in a month after miv-cel met endpoints in a pivotal phase II SPS study.KYTX reported a 46% median improvement in T25FW, showing sustained gains in mobility and stiffness.KYTX plans a BLA filing in H1 2026 for SPS.Kyverna Therapeutics’ (KYTX) lead CAR T-cell therapy candidate, mivocabtagene autoleucel (“miv-cel”, formerly KYV-101), is being developed in a pivotal phase II study for stiff person syndrome (SPS), a rare, debilitating and progressive autoimmune disease with no ...